Chronic Hepatitis Clinical Trial
Official title:
RCT Comparing Different Ribavirin Dosages and Durations of Treatment in Combination With Peginterferon in HCV Genotypes 2 and 3 (WRITE)
WRITE study aim at identifying the effectiveness of an innovative individualized schedule of treatment as compared to standard regimen in patients with chronic HCV genotype 2 and 3.
The investigators are going to compare weight-based dosages of ribavirin, in combination with Peginterferon alpha-2a, with standard fixed dosages of 800 mg. Patients will be evaluated at week 4 with an assay of sensitivity of 15 IU/ml. Patients with week 4 response will discontinue treatment at week 12 in both arms. Patients with HCV RNA still detectable at week 4 and receiving 1000-1200 mg of ribavirin in arm A will discontinue treatment at week 24, whereas patients with HCV RNA still detectable at week 4 and receiving 800 mg of ribavirin in arm B will be treated till week 48. A standard treatment arm (C) including patients treated for 24 weeks with Peginterferon alpha-2a and fixed 800 mg ribavirin dosage will be used as control arm. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT01833611 -
Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT
|
Phase 4 | |
| Completed |
NCT00771446 -
Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03731923 -
Abbreviated MRI for HCC Surveillance
|
N/A | |
| Recruiting |
NCT03013556 -
Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients
|
Phase 4 | |
| Recruiting |
NCT05181826 -
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
|
||
| Active, not recruiting |
NCT02143180 -
Accuracy of RTE for Evaluating Hepatic Fibrosis in Chronic Hepatitis: a Prospective Multicenter Study
|
N/A | |
| Completed |
NCT00596414 -
Sedation and Analgesia for Transjugular Liver Biopsy: A Randomized Double Blind Placebo Controlled Trial
|
Phase 4 | |
| Active, not recruiting |
NCT02772003 -
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
|
Phase 1 | |
| Terminated |
NCT04775797 -
Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection
|
Phase 1 | |
| Terminated |
NCT03487848 -
Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection
|
Phase 2 | |
| Recruiting |
NCT02822079 -
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
|
Phase 1 | |
| Recruiting |
NCT04446832 -
VACcination of LIver Transplantation Candidates
|
||
| Completed |
NCT01121705 -
Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)
|
Phase 3 | |
| Completed |
NCT02742597 -
Patient-Centred Innovations for Persons With Multimorbidity - Ontario
|
N/A | |
| Completed |
NCT05678582 -
Hepatic Steatosis and Chronic Hepatitis B Virus
|
||
| Not yet recruiting |
NCT05062967 -
Evaluation of Orthohepevirus C Infection as an Emerging Cause of Zoonotic Origin Disease
|
||
| Recruiting |
NCT01413360 -
The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients
|
Phase 4 | |
| Terminated |
NCT00496002 -
Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus
|
Phase 3 | |
| Terminated |
NCT00496158 -
Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus
|
Phase 3 | |
| Completed |
NCT02789800 -
Patient-Centred Innovations for Persons With Multimorbidity - Quebec
|
N/A |